Piper Sandler analyst Yasmeen Rahimi initiated coverage of Avalo Therapeutics (AVTX) with an Overweight rating and $48 price target
Piper Sandler analyst Yasmeen Rahimi initiated coverage of Avalo Therapeutics (AVTX) with an Overweight rating and $48 price target